Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	89428
Country	China

Received	2023-10-31 10:11
Peer-Review Started	2023-10-31 10:12
To Make the First Decision
Return for Revision	2023-11-26 12:54
Revised	2023-12-26 13:50
Second Decision	2024-02-07 03:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-07 06:27
Articles in Press	2024-02-07 06:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-08 01:54
Publish the Manuscript Online	2024-04-11 02:23

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Clinical Trials Study
Article Title	Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers
Manuscript Source	Unsolicited Manuscript
All Author List	Zhe-Han Bao, Can Hu, Yan-Qiang Zhang, Peng-Cheng Yu, Yi Wang, Zhi-Yuan Xu, Huan-Ying Fu and Xiang-Dong Cheng
ORCID	Author(s) ORCID Number Can Hu http://orcid.org/0000-0002-8687-8310 Zhi-Yuan Xu http://orcid.org/0000-0002-7257-6856 Huan-Ying Fu http://orcid.org/0000-0002-8489-6275 Xiang-Dong Cheng http://orcid.org/0000-0002-5099-490X
Funding Agency and Grant Number
Corresponding Author	Xiang-Dong Cheng, MD, Dean, Full Professor, Surgeon, Department of Gastric Surgery, Zhejiang Cancer Hospital, No. 1 Mid-level East Road, Hangzhou 310004, Zhejiang Province, China. chengxd@zjcc.org.cn
Key Words	Neoadjuvant therapy; Immunotherapy; Gastric cancer; Borrmann type; Tumor regression grade
Core Tip	Borrmann type III and IV gastric cancers (GCs) generally have a poor prognosis. JCOG0501 failed to demonstrate the efficacy of a preoperative neoadjuvant chemotherapy regimen (S-1 plus cisplatin) in patients with type IV or large type III GC. For these patients, we explored the possibility of chemotherapy combined with immunotherapy. The results showed that programmed cell death 1 inhibitors combined with oxaliplatin and S-1 significantly increased Borrmann III. Tumor regression rate during neoadjuvant therapy in patients with type II and type IV GC. At the same time, chemotherapy side effects and surgical complications did not increase.
Publish Date	2024-04-11 02:23
Citation	Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol 2024; 16(4): 1281-1295
URL	https://www.wjgnet.com/1948-5204/full/v16/i4/1281.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i4.1281

Full Article (PDF)	WJGO-16-1281-with-cover.pdf
CONSORT 2010 Statement	89428-CONSORT 2010 statement.pdf
Manuscript File	89428_Auto_Edited-JLW.docx
Answering Reviewers	89428-Answering reviewers.pdf
Audio Core Tip	89428-Audio core tip.m4a
Biostatistics Review Certificate	89428-Biostatistics statement.pdf
Clinical Trial Registration Statement	89428-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	89428-Conflict-of-interest statement.pdf
Copyright License Agreement	89428-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	89428-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	89428-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	89428-Language certificate.pdf
Supplementary Material	89428-Supplementary material.pdf
Peer-review Report	89428-Peer-review(s).pdf
Scientific Misconduct Check	89428-Bing-Wang JJ-2.png
Scientific Editor Work List	89428-Scientific editor work list.pdf